Tennessee is currently home to 1927 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
PEN-866 in Patients With Advanced Solid Malignancies
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: The West Clinic, Germantown, Tennessee
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Shared-Decision Making for Hydroxyurea
Recruiting
The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences). The study will compare two methods to help clinicians facilitate this-a clinician pocket guide and a clinician hydroxyurea shared decision making toolkit-in a group of parents of children ages 0-5 with sickle cell disease. The investigators hope t... Read More
Gender:
All
Ages:
Between 1 month and 5 years
Trial Updated:
02/09/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Sickle Cell Anemia, Children, Only
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 115, Chattanooga, Tennessee
Conditions: Ischemic Stroke
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Baptist Cancer Center, Memphis, Tennessee
Conditions: Solid Tumors, GI Cancer
Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors
Recruiting
MetaboMed is developing MTB-9655, an orally bioavailable, first-in-class small molecule inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 (ACSS2) enzyme, as a potential treatment for patients with cancer. This study is a Phase 1,First-in-Human (FIH), open-label dose-escalation study of MTB-9655 given daily as a single oral (PO) agent. Up to 30 patients with locally advanced, unresectable and/or metastatic solid tumor(s) are expected to be enrolled in the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2021
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Advanced Solid Tumor
MAP Autism Prediction Study
Recruiting
This pilot clinical trial tests the hypothesis that certain blood metabolite levels can be used to predict Autism Spectrum Disorder (ASD). The study cohort will consist of 200 participants between the ages 18 and 60 months who have been referred to a developmental pediatric center for clinical evaluation of ASD or other developmental delay. Two selected sites will enroll 75 participants each with another 50 typically developing participants. Participants will receive a physical exam (including a... Read More
Gender:
All
Ages:
Between 18 months and 60 months
Trial Updated:
11/03/2021
Locations: VUMC, Nashville, Tennessee
Conditions: Autism Spectrum Disorder, Developmental Delay
Skincare Products and Environmental Health
Recruiting
The purpose of this study is to explore the potential for an association between the development of prepubertal gynecomastia and history exposure to lavender essential oil, tea tree essential oil, and other essential oils.
Gender:
All
Ages:
Between 2 years and 15 years
Trial Updated:
10/29/2021
Locations: Franklin Health Research Center, Franklin, Tennessee
Conditions: Gynecomastia, Endocrine System Diseases
Continuous Monitoring and Control of Hypoglycemia
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee
Conditions: Diabetes
A Tailored, Health Communication Intervention for HPV Vaccine Hesitant Families
Recruiting
The human papillomavirus (HPV) causes 90% of cervical cancers and is implicated in multiple other cancers. The HPV vaccine can prevent the vast majority of these cancers, but it is underused in adolescents, especially among those within vaccine hesitant (VH) parents. The proposed research is to develop and pilot test a tailored, health communication intervention aimed to increase HPV vaccination among VH parents. The proposed research is innovative because no evidence-based health communication... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2021
Locations: Meharry Medical College, Nashville, Tennessee
Conditions: Human Papilloma Virus, HPV-Related Carcinoma, Vaccine Refusal, Parents, Program, Communication
Middle-ear Reflex Testing Using Wideband Acoustic Immittance
Recruiting
This project will assess the middle-ear muscle reflex using wideband acoustic immittance which is a valuable method for evaluating infants, children, and adults. The developments will facilitate clinical applications that include hearing screening and diagnostic evaluation of persons of all ages with normal hearing and with hearing loss.
Gender:
All
Ages:
All
Trial Updated:
07/30/2021
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Hearing Disorders
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
Recruiting
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.
Gender:
Female
Ages:
21 years and above
Trial Updated:
06/24/2021
Locations: ClinSearch, Chattanooga, Tennessee
Conditions: Female Sexual Arousal Disorder
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Recruiting
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
06/07/2021
Locations: Vanderbilt University School of Medicine, Nashville, Tennessee
Conditions: RLS